SEC-sourced researchBeta
BGLC
BioNexus Gene Lab Corp
Company comparison ↗
Data passport
- CIK
- 0001737523
- Exchange
- Nasdaq
- Business activity
- Services-Medical Laboratories · SIC 8071
- Financial inputs
- 6/6
- Filing date
- Nov 19, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 9,510,646.0000 | Apr 14, 2026 |
| December 2025 | 7,424,911.0000 | Apr 14, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 7,424,911.0000 | -2,984,607.0000 | -1,838,382.0000 | 9,252,784.0000 | 637,856.0000 | Apr 14, 2026 |
| December 2024 | 9,510,646.0000 | -1,598,342.0000 | -2,093,260.0000 | 10,433,848.0000 | 2,111,044.0000 | Apr 14, 2026 |
Explainable fundamental score
Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.
44/100
Profitability0
Growth28
Balance sheet93
Cash generation0
Data coverage100
Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $7.42M | Jan 1, 2025 – Dec 31, 2025 | Apr 14, 2026 | 10-K |
| Previous period revenueRevenues | $9.51M | Jan 1, 2024 – Dec 31, 2024 | Apr 14, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$2.98M | Jan 1, 2025 – Dec 31, 2025 | Apr 14, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$1.84M | Jan 1, 2025 – Dec 31, 2025 | Apr 14, 2026 | 10-K |
| Total assetsAssets | $9.25M | Dec 31, 2025 | Apr 14, 2026 | 10-K |
| Total liabilitiesLiabilities | $637.86K | Dec 31, 2025 | Apr 14, 2026 | 10-K |